Pure manipulation today. The wording of the PR for Eltoprazine did softly suggest it could be in early 2015, but I don't think that caused a sell off. It might have been the excuse or opportunity thinking nothing else is coming until next week after the shareholders meeting. I think it was just a typical biotech manipulative walk down triggering some stop losses. If GC said it would be Q4 2015 I would say maybe that was the reason. If they miss some milestones by a few months here and there, it's no big deal, it's biotech. Consistently, it becomes a problem. In my opinion V1 of Lympro was marketable and could have been launched under CLIA and them resubmitted when V2 was validated. I am not really sure that is possible but has been something I have always thought about.